Clinical Decision Support Tool in PARDS Pilot Study

NCT ID: NCT04068012

Last Updated: 2024-10-30

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-01
• Study Completion Date: 2025-07-01

Brief Summary

Previous clinical trials in adults with acute respiratory distress syndrome (ARDS) have demonstrated that ventilator management choices can improve Intensive Care Unit (ICU) mortality and shorten time on mechanical ventilation. This study seeks to scale an established Clinical Decision Support (CDS) tool to facilitate dissemination and implementation of evidence-based research in mechanical ventilation of infants and children with pediatric ARDS (PARDS).

This will be accomplished by using CDS tools developed and deployed in Children's Hospital Los Angeles (CHLA) which are based on the best available pediatric evidence, and are currently being used in an NHLBI funded single center randomized controlled trial (NCT03266016, PI: Khemani). Without CDS, there is significant variability in ventilator management of PARDS patients both between and within Pediatric ICUs (PICUs), but clinicians are willing to accept CDS recommendations. The CDS tool will be deployed in multiple PICUs, targeting enrollment of up to 180 children with PARDS. Study hypotheses:

1. The CDS tool in will be implementable in nearly all participating sites

2. There will be > 80% compliance with CDS recommendations and

3. The investigators can implement automatic data capture and entry in many of the ICUs

Once feasibility of this CDS tool is demonstrated, a multi-center validation study will be designed, which seeks to determine whether the CDS can result in a significant reduction in length of mechanical ventilation (LMV).

Detailed Description

The central hypothesis is that CDS will help standardize ventilator management consistent with evidence-based recommendations leading to shorter LMV by limiting VILI (Ventilator Induced Lung Injury), preventing VIDD (Ventilator Induced Diaphragm Dysfunction) and allowing earlier recognition that patients are ready for liberation from the ventilator. However, key questions must be addressed prior to wide dissemination of this CDS tool:

Specific Aim 1: To assess the feasibility of implementing a web-based, de-identified CDS tool for MV in pediatric ARDS in multiple PICUs. Hypothesis: this CDS tool will be implementable in all PICUs to function consistent with each hospital's specific Information Technology (IT) capabilities.

Specific Aim 2: To assess the acceptability and compliance with recommendations from the CDS tool related to oxygenation, ventilation, weaning and extubation readiness testing in PARDS patients at each of the participating PICUs (anticipated 20 patients enrolled per site). Hypothesis: over time, adherence with recommendations in each of these domains will exceed 80% in all PICUs.

Specific Aim 3: To implement methods for automated data capture within CDS to provide the right information, to the right person, using the right format, in the right channel and at the right time during workflow ("CDS Five Rights") framework, which can be adapted to the individual IT capabilities at each hospital. Hypothesis: Over 90% of necessary data can be pulled into the CDS in an automated fashion in sites which have access to electronic data capture of ventilator settings and blood gases.

Patients will be managed on the eVentilator protocol (the CDS tool), through the acute, stable and weaning phases of mechanical ventilation, including Spontaneous Breathing tests (SBTs) and Extubation Readiness tests.

Data will be qualitatively assessed for implementation barriers. Acceptance and rejection and mode stratification will be examined. Data needed for the CDS protocol will be available electronically or can be interfaced through the bedside monitor.

Patients will be on the CDS protocol, as intent to treat, while patient is on invasive mechanical ventilation, capped at 28 days, limitation of care, or death, whichever comes first.

Conditions

Ventilation Therapy; Complications; Ventilator-Induced Lung Injury; Ards

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Intervention

Ventilator management using the proposed protocol in both acute and weaning phases

Group Type: EXPERIMENTAL

Ventilator protocol

Intervention Type: OTHER

open loop ventilator management by a computer based protocol

Interventions

Ventilator protocol

open loop ventilator management by a computer based protocol

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Children > 1 month of age and >44 weeks gestation and ≤ 18 years of age AND
• Supported on mechanical ventilation with pulmonary parenchymal disease (i.e. Pediatric Acute Respiratory Distress Syndrome (PARDS)) with Oxygen Saturation Index (OSI) ≥ 5) or Oxygenation Index (OI) ≥ 4 AND
• Who are within 72 hours of initiation of invasive mechanical ventilation AND
• Who are anticipated to require >72 hours mechanical ventilation.

Exclusion Criteria

• Conditions on enrollment that preclude conventional methods of weaning (i.e., status asthmaticus, severe lower airway obstruction, bronchiolitis, critical airway, Extra Corporeal Life Support (ECLS), intubation for Upper Airway Obstruction, Do Not Resuscitate orders, severe chronic respiratory failure, spinal cord injury above lumbar region, cyanotic heart disease (unrepaired or palliated)) OR
• Conditions precluding the use of permissive hypercapnia or hypoxemia (i.e. intracranial hypertension, severe pulmonary hypertension)
• Primary Attending physician refuses to enroll the patient

• Minimum Eligible Age: 1 Month
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Children's Hospital Los Angeles

OTHER

Sponsor Role: lead

Responsible Party

Christopher J. L. Newth, MD

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Christopher J Newth, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital Los Angeles

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status: RECRUITING

Riley Hospital for Children

Indianapolis, Indiana, United States

Site Status: RECRUITING

Penn State University

Hershey, Pennsylvania, United States

Site Status: RECRUITING

University of Utah

Salt Lake City, Utah, United States

Site Status: NOT_YET_RECRUITING

University of Wisconsin-Madison

Madison, Wisconsin, United States

Site Status: RECRUITING

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States

Site Status: RECRUITING

CHU Sainte-Justine

Montreal, Quebec, Canada

Site Status: RECRUITING

Ospedale Pediatrico Bambino Gesu

Roma, , Italy

Site Status: NOT_YET_RECRUITING

Countries

United States; Canada; Italy

Central Contacts

Christopher J Newth, MD

Role: CONTACT

cnewth@chla.usc.edu

3233612557

Robinder G Khemani, MD

Role: CONTACT

rkhemani@chla.usc.edu

3233612376

Facility Contacts

Lazaro Sanchez-Pinto

Role: primary

Samer Abu-Sultaneh

Role: primary

Neal Thomas

Role: primary

Anna Hubbard

Role: primary

Awni Al-Subu

Role: primary

Prakadeshwari Rajapreyar

Role: primary

Philippe Jouvet

Role: primary

Fabrizio Chiusolo

Role: primary

References

Hotz JC, Bornstein D, Kohler K, Smith E, Suresh A, Klein M, Bhalla A, Newth CJ, Khemani RG. Real-Time Effort Driven Ventilator Management: A Pilot Study. Pediatr Crit Care Med. 2020 Nov;21(11):933-940. doi: 10.1097/PCC.0000000000002556.

Reference Type: BACKGROUND

PMID: 32976348 (View on PubMed)

Khemani RG, Hotz JC, Klein MJ, Kwok J, Park C, Lane C, Smith E, Kohler K, Suresh A, Bornstein D, Elkunovich M, Ross PA, Deakers T, Beltramo F, Nelson L, Shah S, Bhalla A, Curley MAQ, Newth CJL. A Phase II randomized controlled trial for lung and diaphragm protective ventilation (Real-time Effort Driven VENTilator management). Contemp Clin Trials. 2020 Jan;88:105893. doi: 10.1016/j.cct.2019.105893. Epub 2019 Nov 16.

Reference Type: BACKGROUND

PMID: 31740425 (View on PubMed)

Other Identifiers

CHLA-19-00085

Identifier Type: -

Identifier Source: org_study_id